Search

Your search keyword '"Ko, Song-Chu"' showing total 22 results
Start Over Author "Ko, Song-Chu"
22 results on '"Ko, Song-Chu"'

6. An Ultrasonically Powered Implantable Micro-Oxygen Generator (IMOG)

Author

Maleki, Teimour, Cao, Ning, Song, Seung Hyun, Kao, Chinghai, Ko, Song-Chu, Ziaie, Babak, Maleki, Teimour, Cao, Ning, Song, Seung Hyun, Kao, Chinghai, Ko, Song-Chu, and Ziaie, Babak

Abstract

In this paper, we present an ultrasonically powered implantable micro-oxygen generator (IMOG) that is capable of in situ tumor oxygenation through water electrolysis. Such active mode of oxygen generation is not affected by increased interstitial pressure or abnormal blood vessels that typically limit the systemic delivery of oxygen to hypoxic regions of solid tumors. Wireless ultrasonic powering (2.15 MHz) was employed to increase the penetration depth and eliminate the directional sensitivity associated with magnetic methods. In addition, ultrasonic powering allowed for further reduction in the total size of the implant by eliminating the need for a large area inductor. IMOG has an overall dimension of 1.2 mm x 1.3 mm x 8 mm, small enough to be implanted using a hypodermic needle or a trocar. In vitro and ex vivo experiments showed that IMOG is capable of generating more than 150 mu A which, in turn, can create 0.525 mu L/min of oxygen through electrolytic disassociation. In vivo experiments in a well-known hypoxic pancreatic tumor models (1 cm(3) in size) also verified adequate in situ tumor oxygenation in less than 10 min.

Published
2011

15. MOLECULAR THERAPY WITH RECOMBINANT WT-P53 ADENOVIRUS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN HUMAN CELLS AND RAT EXPERIMENTAL MODELS

Author

Shirakawa, Toshiro, primary, Matsubara, Shigeji, additional, Gotoh, Akinobu, additional, Fujisawa, Masato, additional, Okada, Hiroshi, additional, Arakawa, Soichi, additional, Kamidono, Sadao, additional, Gardner, Thomas A., additional, Wada, Yoshitaka, additional, Ko, Song-Chu, additional, and Kao, Chinghai, additional

Published
1999
Full Text
View/download PDF

17. DEVELOPMENT OF PROSTATE-SPECIFIC ANTIGEN PROMOTER-BASED GENE THERAPY FOR ANDROGEN-INDEPENDENT HUMAN PROSTATE CANCER

Author

GOTOH, AKINOBU, primary, KO, SONG-CHU, additional, SHIRAKAWA, TOSHIRO, additional, CHEON, JUN, additional, KAO, CHINGHAI, additional, MIYAMOTO, TADAYUKI, additional, GARDNER, THOMAS A., additional, HO, LING-JUN, additional, CLEUTJENS, CATHARINA B. J., additional, TRAPMAN, JAN, additional, GRAHAM, FRANK L., additional, and CHUNG, LELAND W. K., additional

Published
1998
Full Text
View/download PDF

22. Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.

Author

Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, Ratliff TL, and Hu CD

Abstract

Prostate cancer remains the most common noncutaneous cancer among American men. Although most patients can be cured by surgery and radiotherapy, 32,050 patients still died of the disease in 2010. Many patients receive radiotherapy either as a primary therapy, salvage therapy, or in combination with surgery or hormonal therapy. Despite initial treatment, several studies suggest that approximately 10% of low-risk prostate cancer patients and up to 30-60% with more advanced cancer patients experience biochemical recurrence within five years after radiotherapy. Thus, elucidating the molecular mechanisms underlying radioresistance and tumor recurrence has the potential to significantly reduce prostate cancer mortality. We previously demonstrated that fractionated ionizing radiation (IR) can induce the prostate cancer cell line LNCaP to undergo neuroendocrine differentiation (NED) by activation of cAMP response element binding protein (CREB) and cytoplasmic sequestration of ATF2, two CRE-binding transcription factors that oppose each other to regulate NED. Importantly, IR-induced NED is reversible and de-differentiated cells are cross-resistant to IR, androgen depletion and docetaxel treatments. These findings suggest that radiation-induced NED may allow prostate cancer cells to survive treatment and contribute to tumor recurrence. In the present study, we further demonstrated that IR also induces NED in a subset of DU-145 and PC-3 cells. In addition, we confirmed that IR induces NED in LNCaP xenograft tumors in nude mice, and observed that the plasma chro-mogranin A (CgA) level, a biomarker for NED, is increased by 2- to 5-fold in tumor-bearing mice after fractionated radiation doses of 20 and 40 Gy, respectively. Consistent with these in vivo findings, a pilot study in prostate cancer patients showed that the serum CgA level is elevated in 4 out of 9 patients after radiotherapy. Taken together, these findings provide evidence that radiation-induced NED is a general therapeutic response in a subset of prostate cancer patients. Thus, a large scale analysis of radiotherapy-induced NED in prostate cancer patients and its correlation to clinical outcomes will likely provide new insight into the role of NED in prostate cancer radiotherapy and prognosis.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results